Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02101593 · ClinicalTrials.gov registry record · Phase 1
Ph 1 Trial of ADI PEG 20 Plus Sorafenib to Treat Patients With Liver Cancer
A Phase 1 study of Hepatocellular Carcinoma, sponsored by Polaris Group.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
- 2
- Study locations
NCT02101593 is a Phase 1 study of Hepatocellular Carcinoma that has completed, run by Polaris Group. The registered enrollment target is 8 participants, below the 257-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (97% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT02101593, a Phase 1 study of Hepatocellular Carcinoma, has completed, sponsored by Polaris Group.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
- 2
- Study locations
Study Summary
Assessment of safety and tolerability of ADI-PEG 20 in combination with sorafenib in advanced Hepatocellular Carcinoma (HCC).
Conditions Studied
Interventions
- DRUG ADI-PEG 20
Study Locations (2)
New York
- Memorial Sloan-Kettering Cancer Center - New York
Washington
- Seattle Cancer Care Alliance - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2014-11 |
| Est. Completion | 2016-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02101593
The ClinicalTrials.gov registry entry for NCT02101593 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 257-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (97% lower). The listed sponsor is Polaris Group, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hepatocellular Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which ADI-PEG 20 is the first listed.
NCT02101593 reports 2 study locations spanning 2 distinct geographic areas - top geographies include New York, Washington.
Frequently Asked Questions
What is clinical trial NCT02101593 about?
NCT02101593 is a clinical study titled "Ph 1 Trial of ADI PEG 20 Plus Sorafenib to Treat Patients With Liver Cancer". Assessment of safety and tolerability of ADI-PEG 20 in combination with sorafenib in advanced Hepatocellular Carcinoma (HCC).
What is the current status of trial NCT02101593?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2014-11. Estimated completion is 2016-03.
What conditions does trial NCT02101593 study?
This clinical trial studies the following conditions: Hepatocellular Carcinoma.
What interventions are being tested in trial NCT02101593?
The interventions under investigation include: ADI-PEG 20 (DRUG).
Who is sponsoring clinical trial NCT02101593?
This trial is sponsored by Polaris Group, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02101593 being conducted?
This trial has 2 study locations across New York, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatocellular Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
RECRUITING · Phase 1
-
Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells
RECRUITING · Phase 1
-
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
RECRUITING · Phase 1
-
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients
RECRUITING · Phase 1
-
Cryoablation and Arterial Infusion of SD-101 in Combination with Durvalumab and Tremelimumab
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.